Modelled DT Structure
Method: multi-sequence alignment based machine learning
Detail: Structure Info
| General Information of DT | |||||
|---|---|---|---|---|---|
| DT ID | DTD0034 | ||||
| Gene Name | SLC18A2 | ||||
| Protein Name | Vesicular amine transporter 2 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| TCDB ID | |||||
| 3D Structure |
Modelled DT Structure Method: multi-sequence alignment based machine learning Detail: Structure Info |
||||
| Synonyms | Monoamine transporter; PKDYS2; SLC18A2; SVAT; SVMT; Solute carrier family 18 member 2; VAT2; VMAT2; Synaptic vesicular amine transporter | ||||
| DT Family | Major Facilitator Superfamily (MFS) | ||||
| Drug:H+ Antiporter-1 (12 Spanner) (DHA1) Family | |||||
| Function | This transporter involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. And it pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. | ||||
| Disease(s) | Neurogenic shock [ICD-11: MG40.Y] | ||||
| Parkinson's Disease [ICD-11: 8A00.0] | |||||
| Endogenous Substrate(s) | Monoamines | ||||
| Variability Data of This Drug Transporter (DT) | |||||
|
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
|
(α) Microbiota Influence of This DT |
|||||
|
(β) Post-translational Modification of This DT |
|||||
|
(γ) Transcriptional Regulation of This DT |
|||||
|
(δ) Epigenetic Regulation of This DT |
|||||
|
(ε) Exogenous Modulation of This DT |
|||||
|
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
|
(β) Inter-species Structural Differences |
|||||
|
General Variability Data of This DT (VARIDT 1.0) |
|||||
|
(α) Genetic Polymorphisms of This DT |
|||||
|
(β) Disease-specific Protein Abundances of This DT |
|||||
|
(γ) Species- and Tissue-specific DT Abundances |
|||||
| Molecular Transporting Profile of This DT | |||||
|
Full List of Drug(s) Transported by This DT |
|||||
|
Approved Drug |
Click to Show/Hide the Full List of Drug: 4 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
Dopamine
|
Approved | Drug Info | Parkinson's Disease | 8A00.0 | [1] |
|
Ergotidine
|
Approved | Drug Info | Migraine | 8A80 | [2] |
|
Methamphetamine
|
Approved | Drug Info | Attention deficit hyperactivity disorder | 6A05 | [3] |
|
Norepinephrine
|
Approved | Drug Info | Septic shock | 1G41 | [1] |
|
Endogenous Metabolites (EMs) Handled by This DT |
|||||
|
Endogenous Metabolites (EMs) |
Click to Show/Hide the Full List of EMs: 6 EMs in Total | ||||
| EM Name | PubChem CID | Detail | Experimental Material | Ref | |
| Choline | EM Info | Identified using VMAT2-deficient mice | [4] | ||
| Creatine | EM Info | Identified using VMAT2-deficient mice | [4] | ||
| Glutamate | EM Info | Identified using VMAT2-deficient mice | [4] | ||
| Myo-inositol | EM Info | Identified using VMAT2-deficient mice | [4] | ||
| Phosphocholine | EM Info | Identified using VMAT2-deficient mice | [4] | ||
| Taurine | EM Info | Identified using VMAT2-deficient mice | [4] | ||
| References | |||||
| 1 | SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72. | ||||
| 2 | The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014 Jul;73:89-97. | ||||
| 3 | Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter. J Med Chem. 2018 Oct 25;61(20):9121-9131. | ||||
| 4 | A metabolomic study of brain tissues from aged mice with low expression of the vesicular monoamine transporter 2 (VMAT2) gene. Neurochem Res. 2008 Feb;33(2):292-300. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.